Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von OldOrangeEyes 

Acadia Pharmaceuticals diskutieren

Acadia Pharmaceuticals

WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

15,62 €
1,45 %

Einschätzung Buy
Rendite (%) -28,37 %
Kursziel 30,43
Veränderung
Endet am 28.02.25

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat

Einschätzung Buy
Rendite (%) -14,20 %
Kursziel 29,32
Veränderung
Endet am 12.03.25

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Needham & Company LLC from $36.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,74 %
Kursziel 27,59
Veränderung
Endet am 18.03.25

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Morgan Stanley from $40.00 to $30.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,36 %
Kursziel 23,06
Veränderung
Endet am 25.03.25

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,60 %
Kursziel 29,40
Veränderung
Endet am 09.04.25

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,36 %
Kursziel 34,38
Veränderung
Endet am 10.04.25

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,12 %
Kursziel 34,52
Veränderung
Endet am 30.04.25

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat